Moderna Inc (MRNA)
$122.39
0.11 (0.09%)
MRNA Stock Quote Delayed 30 Minutes
Stock Market Today: Facebook Shops; Amazon Acquires J.C. Penney?
Facebook is launching a Shops feature, while Apple buys up old video content. Here's what's happening in the stock market today.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
46.87B
PE Ratio
-7.82
EPS
-15.66
Volume (Avg. Vol.)
376,831
Day's Range
$120.22 - $123.20
52-Week Range
$62.55 - $170.47
Dividend & Yield
N/A (N/A)
MRNA Stock Predictions, Articles, and Moderna Inc News
Can Moderna Stock Keep Its Place At the Front of the Pack?
MRNA stock jumped on the news its mRNA-1273 vaccine will start phase 2 trials any day, but now many question whether the hype is justified.
Moderna News: MRNA Stock Soars 11% on Covid-19 Vaccine Phase 2 Trial
Moderna (MRNA) news for Thursday concerning a Phase 2 trial of its vaccine to treat the novel coronavirus has MRNA stock heading higher.
The Best Thing Happening During These ‘Worst of Times’
The coronavirus has led to a lot of bad news and tough times, but investors can profit from companies that are bringing us hope.
The Trends are Mostly Friendly for Moderna Stock Investors
There’s a lot of bullish trends working in Moderna’s favor, but right now there’s also plenty of ‘ifs’ to be worked out before allocating risk capital into the stock
Here’s Why It’s Not Too Late to Load Up on Moderna Stock
While there are no guarantees with drug development, MRNA stock investors have high hope that Moderna can help wipe out this global virus.
Why Investors Should Avoid Inovio Pharmaceuticals
Investors should avoid INO stock and buy MRNA stock instead on weakness because Moderna's credentials are much more impressive at this point.
Moderna Stock Is Near Highs, But Faces Risk
The Moderna team is working hard at bringing the world a Covid-19 vaccine. Perhaps investors have too much faith in the MRNA stock too soon.
Moderna Stock Is Still Worth a Buy While It’s in Breakout Mode
Moderna got the green light from a well-funded source, which has sent MRNA stock on a tear and makes it a promising stock to buy.
Moderna Scores Huge Grant, Leads Charge Toward Coronavirus Vaccine
Moderna pulled in a massive $483 million government grant to develop a Covid-19 vaccine. As a result, MRNA stock will continue to be a winner.
Moderna Faces Tough Threats in the Short and Long Term
Moderna is facing meaningful short-term and longer-term threats. As a result, investors should sell MRNA stock at this point.
3 Big Stock Charts for Monday: Boeing, AMC Entertainment, and Moderna
Monday's big stock charts feature names that buyers went absolutely crazy over.
4 Top Stock Trades for Monday: BA, MRNA, SLB, KSU
Moderna, Kansas City Southern, Boeing and Schlumberger were our top stock trades for Monday. That said, here's a look at the charts.
Moderna News: MRNA Stock Surges on Potential Coronavirus Vaccine
Moderna news regarding federal funding for the company to advance its possible coronavirus vaccine has MRNA stock rising fast on Friday.
2 Pros, 2 Cons for Investing in Moderna as It Develops Coronavirus Vaccine
With the world under seige from the coronavirus pandemic, an investment like MRNA stock appears incredibly relevant. Still, you should consider some risk factors before diving in.
Moderna Stock Is the Greatest Coronavirus Speculation Play
Moderna was able to quickly develop a vaccine candidate because Covid-19 is similar to MERS, which it had been working on for two years.
Moderna’s Vaccine Race Is Compelling But Risky
While MRNA stock makes for a good speculative bet, today's market is far too uncertain to be making risky investments in unproven technology.
INO Stock May Fade After the Virus, but It Could Rocket to $20 First
With phase one of human trials underway, we may be closer than ever to putting the virus to bed. Before that happens, INO stock will run.
Moderna Emerges as Coronavirus Vaccine Leader
Even with the sense of urgency surrounding coronavirus treatments, developers need to worth their way through the regulatory process, one that dictates it could be a year or more before a COVID-19 vaccine, such as Moderna's mRNA-1273, could be made available to patients. As such, it could be another couple of months before the company's Phase 1 data is made public.
